Search academic texts

Information × Registration Number 0211U005218, 0107U012347 , R & D reports Title Experimental study of the polypeptide EMAP-II and flutafarm (flutamide) effect on androgen-dependent and cancerous processes in the prostate popup.stage_title Head Reznikov Olexander Grigorovych, Registration Date 04-03-2011 Organization State Institution "V.P. Komisarenko Institute of Endocrinology and Metabolism оf the Academy of Medical Scienses of Ukraine" popup.description2 Object: xenografts of human prostate adenocarcinoma, rat prostate. Aim of study: еxperimental study of EMAP-II and Flutamide or their combinations ability to retard growth of human prostate adenocarcinoma and androgen-dependent processes in the prostate. Methods: biological, biochemical, morphological. Basic and practice results: Administration of the recombinant cytokine-like polypeptide EMAP-II (endothelial-monocyte activating polypeptide-II) at the doses ranging from 5 to 200 mcg/kg b.w. inhibited growth of human prostate adenocarcinoma xenografts in CBA mice. Histological examination revealed stimulation of apoptosis and an enlargement of necrosis area. Using TUNEL techniques the cells having eruptions of DNA threads and significant increase of the quantity of the cells at irreversible apoptotic phase were identified. Being administered subcutaneously or intraabdominally as solution or liophylizate, EMAP-II demonstrated equal efficacy. Antitumor effects were enhanced by combined treatment with EMAP-II and antiandrogen Flutamide. Similarly, synergistic effect of the drugs was observed in immature castrated rats under testosterone propionate replacement therapy. There were obtained new data on the mechanisms of EMAP-II activities, in particular, regarding its ability to inhibit androgen-dependent angiogenesis and epithelium proliferation in the prostate. Those effects were enhanced by adding Flutamide, that might contribute to development of new methods of hormonal therapy of prostate cancer. Priority results: At first antiangiogenic and pro-apoptotic effects of EMAP-II in the rat prostate tissues, as well as antitumorous and pro-apoptotic effects in human prostate adenocarcinoma tissues were found. Implementation: These results should be taken into consideration for improvement of therapy and life quality in the patients suffering from prostate cancer. Advantages: New methods of suppressive influence on prostate adenocarcinoma with separate use of recombinant polypeptide EMAP-II or its combination with antiandrogen Flutamide are being proposed. Fields of interest: еndocrinology, oncourology. Product Description popup.authors Боброва Т.Ю. Полякова Л.І. Резніков О.Г. Сачинська О.В. Чайковська Л.В. popup.nrat_date 2020-04-02 Close